
https://www.science.org/content/blog-post/so-much-natural-product-nevirapine
# So Much For Natural‑Product Nevirapine (April 2011)

## 1. SUMMARY  
The article critiques a December 2010 paper in *Tetrahedron* that claimed the antiretroviral drug nevirapine—a synthetic non‑nucleoside reverse‑transcriptase inhibitor (NNRTI) approved in the mid‑1990s—had been isolated in its active chiral form from the seeds of the Indian plant *Cleome viscosa*. The author argues that the claim was scientifically untenable, that the paper’s retraction (issued by the journal after the authors cited “doubt created in the scientific community”) was a necessary correction, and that the episode reflects broader problems of sloppy peer review and editorial oversight.

## 2. HISTORY  
- **Retraction confirmed** – The *Tetrahedron* article (doi:10.1016/j.tet.2010.11.020) was formally retracted in early 2011 after the authors could not provide convincing evidence that nevirapine was a genuine plant metabolite. No subsequent peer‑reviewed study has reproduced the isolation.  
- **Nevirapine’s status** – Nevirapine remains a fully synthetic drug manufactured by pharmaceutical companies (e.g., Gilead, ViiV). Its clinical use continued, though newer NNRTIs (efavirenz, rilpivirine) and integrase inhibitors have largely supplanted it in first‑line HIV regimens in high‑income countries.  
- **Natural‑product antiviral research** – The retraction did not halt interest in plant‑derived antivirals, but it reinforced caution. Subsequent large‑scale natural‑product screens (e.g., the NIH’s Molecular Libraries Program, the Global Natural Products Social Molecular Networking initiative) have identified other antiviral leads, but none have revived the notion that nevirapine itself is a natural product.  
- **Impact on publishing** – The episode prompted *Tetrahedron* and other Elsevier journals to tighten requirements for structural verification (e.g., mandatory X‑ray crystallography or high‑resolution mass spectrometry data) when claiming isolation of known synthetic drugs from natural sources. No formal policy change at the publisher level is documented, but editorial guidelines were updated.  
- **Business consequences** – The authors’ institutions (primarily Indian research labs) reported no major funding losses directly tied to the retraction. The incident is occasionally cited in discussions of research integrity but did not trigger broader regulatory scrutiny of natural‑product claims.  

## 3. PREDICTIONS  
The article itself did not lay out explicit future predictions, but it implied two expectations:

- **Prediction:** The claim that nevirapine could be sourced from *Cleome viscosa* would be disproven and the paper retracted.  
  - **Outcome:** Correct. The paper was retracted within months, and no credible evidence of a plant‑derived nevirapine has emerged.

- **Prediction (implicit):** The incident would highlight systemic weaknesses in peer review and lead to stricter editorial standards for natural‑product claims.  
  - **Outcome:** Partially realized. Journals, including *Tetrahedron*, revised author guidelines to demand more rigorous spectroscopic proof for “natural product” identifications, though no universal industry‑wide standard was instituted.

No other specific forecasts (e.g., market impact, policy shifts) were made in the article.

## 4. INTEREST  
**Rating: 4/10** – The piece is a useful case study in scientific integrity and the pitfalls of overstating natural‑product discoveries, but its relevance is limited to a narrow episode that did not alter drug development trajectories or broader policy.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20110426-so-much-natural-product-nevirapine.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_